Diligence memo · auto-generated · as of July 2, 2026
Etheros Pharmaceuticals Corp.
Etheros Pharmaceuticals Corp. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Etheros Pharmaceuticals Corp. operates in Pharmaceuticals, based in NASHVILLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Etheros Pharmaceuticals Corp. has raised $1.7M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $775K on 2023-02-20.
Most recent recorded round closed around 2025-01-31.
Valuation (modeled)modeled
Provath models Etheros Pharmaceuticals Corp. at approximately $1.9M (range $336K–$5.4M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.32× the median modeled value of Pre-Seed Pharmaceuticals companies in 2025–2027 (19 peers) — value vs value, same stage and era. Within the normal band (132% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 12 months.
Last raise 17 mo ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
The last round stepped up 2.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 25% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 4% of those peers.
Closest niche peers: Fedora Pharmaceuticals Inc., PRG FlowChem, Inc., Adora Animal Health Corp, ABLi Therapeutics, Inc., NextEvo, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.